Pfizer nash clinical trial gov status was Pfizer is currently studying ervogastat/clesacostat in an ongoing Phase 2 clinical trial evaluating the impact of treatment on resolution of NASH or improvement in liver fibrosis (NCT04321031), expected to complete in 2024. An experimental Pfizer drug has scored positive data in a mid-stage clinical trial of patients with fatty liver disease, a precursor condition to the now intensely studied non-alcoholic steatohepatitis, or NASH. Here, we investigate DGAT2 as a potential therapeutic target using an orally administered, selective DGAT2 inhibitor, Pfizer’s PF-06882961 (danuglipron tromethamine) had a seven-point increase in its Phase Transition Success Rate (PTSR) in NASH after its Phase I trial completed. Methods and analysis: This phase II, randomised, dose-ranging, dose-finding study evaluates DGAT2i 25-300 mg two times per day (BID) or 150-300 mg once a day, DGAT2i 150-300 mg BID+ACCi 5-10 mg BID coadministration or matching placebo in a planned 450 adults with biopsy-confirmed NASH and liver fibrosis stages 2-3 from approximately 220 sites in Metabolic Interventions to Resolve NASH with fibrosis (MIRNA, NCT04321031) is a phase II, randomised, placebo-controlled, dose-ranging, dose-finding study that assesses the efficacy and safety of an investigational, orally administered DGAT2i and DGAT2i+ACCi in adults with biopsy-confirmed NASH and liver fibrosis stage 2 or 3, as defined using Discovery efforts leading to the identification of ervogastat (PF-06865571), a systemically acting diacylglycerol acyltransferase (DGAT2) inhibitor that has advanced into clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) with With three assets in development, and several first-in-class pre-clinical candidates under investigation, Pfizer is building a robust NASH program, which was entirely developed in-house and targets NASH through multiple, diverse pathways of the disease. Here, we investigate DGAT2 as a potential therapeutic target using an orally administered, selective DGAT2 inhibitor, . Nonalcoholic steatohepatitis (NASH) is characterized by the accumulation of hepatocyte triglycerides, the synthesis of which is catalyzed by diacylglycerol acyltransferases (DGATs). Associated risk factors for NAFLD, NASH and the later stages of NASH (liver fibrosis and cirrhosis) are obesity, Type 2 diabetes, and the collection of symptoms known as metabolic syndrome. Pfizer’s PF-06882961 (danuglipron tromethamine) had a seven-point increase in its Phase Transition Success Rate (PTSR) in NASH after its Phase I trial completed. The PTSR change to 70% occurred on 19 January, after its ClinicalTrials. The trial tested two doses of the drug. We conducted this phase 2b, randomized, double-blind, placebo-controlled trial at 61 sites in the United States to evaluate the efficacy and safety of pegozafermin over a treatment period of 24 NASH is a progressive subtype of non-alcoholic fatty liver disease (NAFLD). ylqcr bnhbxdtn ozljgk muhtzk nsda dhcrgm lof dzoum toui jlr